OXALIPLATIN TREATMENT IN HEAVILY PRETREATED PATIENTS (PTS) WITH RECURRENT OVARIAN CARCINOMA (ROC) COULD BE AN EFFECTIVE TREATMENT IN PTS WITH HYPERSENSIBILITY REACTIONS (HSR) TO CARBOPLATIN

被引：0
|
作者：
Manzano, A. [1 ]
Abad, P. [2 ]
Marquina, G. [1 ]
Cabezas, S. [1 ]
Vila, C. [1 ]
Gonzalez, J. [1 ]
Coronado, P. [3 ]
Cordoba, S. [4 ]
Mendez, R. [5 ]
Diaz-Rubio, E. [1 ]
Casado, A. [1 ]
机构：
[1] Hosp Univ Clin San Carlos, Dept Med Oncol, Madrid, Spain
[2] Univ Complutense, Dept Med, E-28040 Madrid, Spain
[3] Hosp Clin San Carlos, Dept Gynecol, Madrid, Spain
[4] Hosp Clin San Carlos, Radiotherapy Oncol Dept, Madrid, Spain
[5] Hosp Clin San Carlos, Dept Radiol, Madrid, Spain
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2015年 / 25卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ESGO-1099
引用
收藏
页码：1431 / 1432
页数：2
相关论文
共 37 条
  • [21] PHASE-I CLINICAL-TRIAL OF RECOMBINANT HUMAN INTERLEUKIN-3 COMBINED WITH CARBOPLATIN IN THE TREATMENT OF PATIENTS WITH RECURRENT OVARIAN-CARCINOMA
    RUSTHOVEN, JJ
    EISENHAUER, E
    MAZURKA, J
    HIRTE, H
    OCONNELL, G
    MULDAL, A
    LU, HX
    ONETTO, N
    SWENERTON, K
    JEFFREY, J
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (10) : 823 - 825
  • [22] Carboplatin (C) and docetaxel (D) in second-line treatment of non-small cell lung cancer (NSCLC) patients (PTS) pretreated with platinum-based combinations (PBC): A phase II trial
    Buffoni, Lucio
    Fea, Elena
    Numico, Gianmauro
    Dongiovanni, Diego
    Barone, Carla
    Schena, Marina
    Colantonio, Ida
    Occelli, Marcella
    Mattiot, Valentina Polla
    Merlano, Marco
    ANNALS OF ONCOLOGY, 2007, 18 : 31 - 31
  • [23] Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study.
    Oza, Amit M.
    Cibula, David
    Oaknin, Ana
    Poole, Christopher John
    Mathijssen, Ron H. J.
    Sonke, Gabe S.
    Colombo, Nicoletta
    Spacek, Jiri
    Vuylsteke, Peter
    Hirte, Hal W.
    Mahner, Sven
    Plante, Marie
    Schmalfeldt, Barbara
    Mackay, Helen
    Rowbottom, Jacqui
    Tchakov, Ilian
    Friedlander, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] Carboplatin-vinorelbine (CBDCA-VNB): An effective and well-tolerated first-line treatment in advanced non-small cell lung cancer (NSCLC) patients (PTS)
    Cremonesi, M
    Cazzaniga, M
    Ciotti, R
    Barni, S
    ANNALS OF ONCOLOGY, 2000, 11 : 3 - 3
  • [25] Time to treatment failure (TTF) and treatment beyond progression (TBP) in pretreated metastatic renal cell carcinoma (mRCC) patients (pts) receiving nivolumab: A survival outcome and a therapeutic strategy of clinical benefit (meet-uro 15)
    Rebuzzi, S. E.
    Signori, A.
    Buti, S.
    Maruzzo, M.
    De Giorgi, U. F. F.
    Zucali, P. A.
    Procopio, G.
    Fratino, L.
    Pipitone, S.
    Mollica, V.
    Soraru, M.
    Chiellino, S.
    Lipari, H.
    Galli, L.
    Masini, C.
    Naglieri, E.
    Milella, M.
    Ricotta, R.
    Banna, G. L.
    Fornarini, G.
    ANNALS OF ONCOLOGY, 2023, 34 : S1020 - S1020
  • [26] Weekly paclitaxel (P), carboplatin (CP) plus pembrolizumab (PMB) as first-line treatment of recurrent or metastatic (R/M) or locally very advanced (LVA) head and neck squamous cell carcinoma (HNSCC): A retrospective study in 39 patients (pts).
    Borel, Christian
    Carinato, Helene
    Pflumio, Carole
    Poprawa, Elodie
    Brahimi, Youssef
    Oriel, Marine
    Vacheret, Clara
    Ravily, Delphine
    Coliat, Pierre
    Petit, Thierry
    Burgy, Mickael
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] Real-world (RW) systemic treatment patterns and clinical outcomes in locally advanced (LA) and recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC) patients (pts).
    Thao Vo
    Boyd, Marley
    Espirito, Janet L.
    Gumuscu, Burak
    Chirovsky, Diana Romana
    Robert, Nicholas J.
    Swaby, Ramona F.
    Zhou, Wei
    Cowey, Charles Lance
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [28] Phase 2 trial of enoblituzumab plus retifanlimab or tebotelimab in first-line treatment of patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
    Obara, Grzegorz
    Sun, Jichao
    Loo, Deryk
    Bohac, Gerry C.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [29] A multicenter randomized phase II study of paclitaxel (P) and carboplatin (C) versus oral vinorelbine (oV) and carboplatin (C) as second-line treatment in patients (pts) with non-small cell lung cancer (NSCLC) pretreated with non-platinum based chemotherapy
    Agelaki, S.
    Syrigos, K.
    Polyzos, A.
    Agelidou, A.
    Handrinos, V
    Kotsakis, A.
    Christophyllakis, Ch
    Vardakis, N.
    Georgoulias, V
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S447 - S448
  • [30] A multicenter phase II study of the efficacy and safety of quisinostat (an HDAC inhibitor) in combination with paclitaxel and carboplatin chemotherapy (CT) in patients (pts) with recurrent platinum resistant high grade serous epithelial ovarian, primarily peritoneal or fallopian tube carcinoma cancer (OC).
    Tjulandin, Sergei
    Fedyanin, Mikhail
    Vladimirov, Vladimir Ivanovich
    Kostorov, Vladimir
    Lisyanskaya, Alla Sergeevua
    Krikunova, Ludmila
    Cakana, Andrew
    Azarova, Valeria
    Karavaeva, Oksana
    Vostokova, Natalia
    Baranovsky, Sergey
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
1234